|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Findings suggested that increasing in serum OPG was consistent with CAC and could be used for the early diagnosis of subclinical atherosclerosis.
|
30747085 |
2019 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher circulating OPN and OPG levels have been associated with the presence of insulin resistance, atherosclerosis and coronary heart disease.
|
30132286 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression.
|
31642412 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies showed that key proteins of bone metabolism, such as osteoprotegerin (OPG) and osteopontin (OPN), are also involved in vascular atherosclerosis and calcifications.
|
30791743 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Study of the osteoprotegerin/receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis.
|
29336616 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We postulate that circulating OPG may play a dual role as a marker for both medial arterial calcification and atherosclerosis, hence it seems to be a valuable tool for assessing CV risk in patients with CKD.
|
29974642 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
OPG is steadily released from vascular endothelial cells in response to inflammatory stimuli, suggesting that it plays a modulatory role in vascular injury, inflammation, and atherosclerosis.
|
28867452 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis.
|
28837646 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relation between osteoprotegerin, inflammatory processes, and atherosclerosis in patients with metabolic syndrome.
|
29077157 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily and is involved in the progress of atherosclerosis.
|
28249772 |
2017 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
OPG, but not fetuin-A levels, are independently associated with overall mortality, as well as clinical and subclinical atherosclerosis and cardiac function, in prevalent hemodialysis patients.
|
28882110 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the current study were to assess the prevalence of premature atherosclerosis among our B-TM patients, and to investigate the diagnostic value of serum Osteoprotegerin assay as an early biomarker for atherosclerosis.
|
28279156 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiligand receptor for advanced glycation end products (RAGE), osteoprotegerin, and Golgb1 genes may be implicated in atherosclerosis and vascular diseases.
|
26664786 |
2015 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to evaluate OPG concentration in patients with MS and its association with subclinical atherosclerosis and coronary arterial calcification (CAC).
|
25218813 |
2014 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
OPG has been hypothesized to modulate vascular functions; however, its role in mediating atherosclerosis is controversial.
|
25323324 |
2014 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis factor receptor family and plays a role in atherosclerosis.
|
22965192 |
2013 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is now emerging evidence that OPG participates in the pathogenesis of atherosclerosis and cardiovascular diseases by amplifying the adverse effects of inflammation and several traditional risk factors such as hyperlipidemia, endothelial dysfunction, diabetes mellitus, and hypertension.
|
23110639 |
2013 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
|
21568931 |
2011 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that OPG promotes VSMC proliferation and might be directly involved in pathogenetic aspects of atherosclerosis.
|
19907187 |
2010 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
LHGDN |
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
|
17804683 |
2007 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) has recently been identified in atherosclerosis.
|
15939823 |
2005 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry and in situ hybridization revealed OPG immunoreactivity and mRNA expression surrounding calcified areas in the medial layer (Mönckeberg's sclerosis), whereas OPG was mainly expressed adjacent to calcified neointimal lesions (atherosclerosis).
|
15292354 |
2004 |